All In MedTech

Device Trial Radar · NCT07912541

ADVA ACE Coronary Stent System in Coronary Artery Disease Patients (ADVANCE)

A Prospective, Global, Multi-centre, Single-arm Clinical Study to Evaluate the Safety and Performance of ADVA ACE Everolimus elutiNg Coronary Stent System in Coronary Artery Disease in Indian & European Population (ADVANCE)

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

110

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Nov 2028

Study completion May 2029

Sponsor

Lead sponsor
Advanced MedTech Solutions Pvt. Ltd.Academic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Clicebo Solutions Private Limited
First posted
Nov 3, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A prospective, global, multi-centre, single-arm clinical study to evaluate the Safety and Performance of ADVA ACE Everolimus eluting Coronary Stent System in Coronary Artery Disease in Indian \& European population. To evaluate the performance of ADVA ACE Everolimus Eluting Stent, follow up indicated by MACE at 6 months. Of the 110, 40 patients will be assigned to European population, and 70 patients will be assigned to Indian population. QCA is applicable to all Indian patients while OCT applicable for 10 Indian patients only at baseline and 6-months follow-up visit. A QCA Analysis will be performed on all 70 patients in Indian population \& 10 Indian patients only. Interval (Days) for patients visit at Day 0, Day 30±14, Day 180±14 and Day 360±14.

Conditions

  • Coronary Artery Disease
  • De Novo Stenosis Lesion
  • Coronary Stent Implantation

Interventions

  • ADVA ACE Everolimus Eluting Coronary Stent SystemDevice

    ADVA ACE - Everolimus Eluting Coronary Stent System is a device/drug combination product comprised of two regulated components: a device (coronary stent system) and a drug product (a formulation of Everolimus contained in a biodegradable polymer coating). is uniquely designed with a low polymer load, abluminal coating and bioabsorbable polymer matrix which may reduce the risk of thrombosis and the need for prolonged dual antiplatelet therapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major adverse cardiac events (MACE) - defined as composite of cardiovascular death, non-fatal myocardial infarction (MI), and clinically driven target vessel revascularization (CD-TVR)Time frame: 180 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.